Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CLRB 
Cellectar Biosciences Inc (CLRB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: CLRB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $120
1 Year Target Price $120
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.32% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.17M USD | Price to earnings Ratio - | 1Y Target Price 120 |
Price to earnings Ratio - | 1Y Target Price 120 | ||
Volume (30-day avg) 4 | Beta 0.42 | 52 Weeks Range 4.36 - 68.70 | Updated Date 08/13/2025 |
52 Weeks Range 4.36 - 68.70 | Updated Date 08/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -18.9 |
Earnings Date
Report Date 2025-08-11 | When Before Market | Estimate -0.133 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -97.92% | Return on Equity (TTM) -208.72% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -224793 | Price to Sales(TTM) - |
Enterprise Value -224793 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.25 | Shares Outstanding 2857040 | Shares Floating 1508515 |
Shares Outstanding 2857040 | Shares Floating 1508515 | ||
Percent Insiders 2.15 | Percent Institutions 6.27 |
Upturn AI SWOT
Cellectar Biosciences Inc
Company Overview
History and Background
Cellectar Biosciences Inc. was founded in 2006 and focuses on the discovery, development, and commercialization of phospholipid drug conjugates (PDCs) for the treatment of cancer.
Core Business Areas
- PDC Therapeutics: Development of phospholipid drug conjugates (PDCs) for targeted cancer therapies. Their lead asset is CLR 131.
- Clinical Development: Conducting clinical trials to evaluate the safety and efficacy of PDC therapies.
- Intellectual Property: Maintaining and expanding a portfolio of patents related to PDC technology.
Leadership and Structure
James Caruso serves as the President and CEO. The company operates with a management team focused on clinical development, research, and business development. The company has a board of directors which oversees the companyu2019s strategy and direction.
Top Products and Market Share
Key Offerings
- CLR 131 (Iopofosine I 131): CLR 131 is a phospholipid drug conjugate (PDC) designed to deliver targeted radiation directly to cancer cells. It is in clinical development for hematologic malignancies, including multiple myeloma. There is no direct market share data to provide for a drug that is still in the clinical trial stage. Competitors include established therapies for multiple myeloma and other hematologic cancers. Major companies like GSK, Bristol Myers Squibb, Johnson & Johnson, and Amgen develop competing treatments.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically oncology, is characterized by intense competition, high regulatory hurdles, and significant research and development investments. Targeted therapies like PDCs are gaining prominence due to their potential for improved efficacy and reduced side effects compared to traditional chemotherapy.
Positioning
Cellectar Biosciences is positioned as a developer of targeted cancer therapies using its PDC platform. Its competitive advantage lies in the potential of PDC technology to selectively deliver therapeutic payloads to cancer cells, improving treatment outcomes.
Total Addressable Market (TAM)
The total addressable market for multiple myeloma treatment is projected to reach billions of dollars annually. Cellectar, if successful, could capture a portion of this market with CLR 131. The TAM for relapsed/refractory multiple myeloma alone is significant.
Upturn SWOT Analysis
Strengths
- Novel PDC platform for targeted drug delivery
- Clinical-stage asset (CLR 131) with promising early data
- Experienced management team
- Strong IP Portfolio
Weaknesses
- Limited financial resources
- Dependence on a single lead asset (CLR 131)
- High risk associated with clinical development
- Limited commercial infrastructure
Opportunities
- Potential to partner with larger pharmaceutical companies
- Expansion of PDC platform to other cancer types
- Positive clinical trial results leading to regulatory approval
- Orphan drug designation and accelerated approval pathways
Threats
- Clinical trial failures
- Competition from established therapies and other emerging technologies
- Regulatory hurdles and delays
- Difficulty in securing funding
Competitors and Market Share
Key Competitors
- BMY
- GSK
- JNJ
- AMGN
Competitive Landscape
Cellectar's PDC platform offers a unique approach to targeted cancer therapy. However, it faces intense competition from established pharmaceutical companies with marketed therapies and other emerging biotechnology companies developing novel cancer treatments. Its success hinges on demonstrating superior efficacy and safety compared to existing options.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company being in the clinical development stage.
Future Projections: Future growth depends on the successful development and commercialization of CLR 131. Analyst estimates vary widely due to the inherent risks associated with biotechnology companies. Positive clinical trial data will dramatically increase the projected growth.
Recent Initiatives: Recent initiatives include advancing CLR 131 through clinical trials, seeking strategic partnerships, and exploring new applications for the PDC platform.
Summary
Cellectar Biosciences is a clinical-stage biopharmaceutical company with a promising PDC technology. The company's success relies heavily on the successful clinical development of CLR 131. The company faces substantial risks, including clinical trial failures and competition from larger pharmaceutical companies. However, positive clinical results and strategic partnerships could drive significant growth. The company has a novel approach and a strong IP, but is still high risk and has limited financial resources.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cellectar Biosciences Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2005-11-10 | President, CEO & Director Mr. James V. Caruso | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://www.cellectar.com |
Full time employees 11 | Website https://www.cellectar.com | ||
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.